Exane Derivatives Incyte Corp Transaction History

Exane Derivatives

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$66.02 - $79.71 $161,154 - $194,572	-2,441 Closed	0 $0
Q4 2021 Jan 28, 2022	BUY	$63.34 - $74.11 $45,414 - $53,136	717 Added 41.59%	2,441 $0
Q3 2021 Oct 26, 2021	BUY	$68.67 - $84.02 $8,515 - $10,418	124 Added 7.75%	1,724 $0
Q2 2021 Jul 28, 2021	BUY	$79.87 - $87.53 $51,995 - $56,982	651 Added 68.6%	1,600 $0
Q1 2021 Apr 30, 2021	SELL	$76.02 - $100.5 $47,740 - $63,114	-628 Reduced 39.82%	949 $0
Q4 2020 Jan 27, 2021	BUY	$80.74 - $97.7 $20,911 - $25,304	259 Added 19.65%	1,577 $0
Q3 2020 Oct 06, 2020	BUY	$85.07 - $109.69 $16,503 - $21,279	194 Added 17.26%	1,318 $0
Q2 2020 Jul 10, 2020	SELL	$74.18 - $108.93 $46,881 - $68,843	-632 Reduced 35.99%	1,124 $0
Q1 2020 Apr 17, 2020	BUY	$63.18 - $85.97 $93,190 - $126,805	1,475 Added 524.91%	1,756 $0
Q4 2019 Jan 22, 2020	BUY	$73.04 - $95.72 $5,989 - $7,849	82 Added 41.21%	281 $0
Q2 2019 Jul 12, 2019	BUY	$73.52 - $88.7 $14,630 - $17,651	199 New	199 $0
Q4 2018 Jan 31, 2019	SELL	$58.5 - $69.94 $259,272 - $309,974	-4,432 Closed	0 $0
Q3 2018 Oct 24, 2018	SELL	$61.75 - $74.23 $4.32 Million - $5.2 Million	-70,019 Reduced 94.05%	4,432 $0
Q2 2018 Jul 19, 2018	BUY	$60.85 - $83.98 $3.71 Million - $5.13 Million	61,035 Added 454.94%	74,451 $0
Q1 2018 Apr 30, 2018	BUY	$83.06 - $100.98 $527,098 - $640,819	6,346 Added 89.76%	13,416 $0
Q4 2017 Jan 29, 2018	BUY	$93.56 - $116.6 $661,469 - $824,362	7,070	7,070 $0

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.